Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout
By Sydney Price · June 10, 2026, 9:57 PM EDT
An investor of rare disease treatment company Catalyst Pharmaceuticals Inc. is attempting to stop a buyout by Italian rival Angelini Pharma SpA, saying Catalyst's deficient proxy statement omits relevant information regarding...
To view the full article, register now.